ANTONUZZO, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.621
AS - Asia 10.671
EU - Europa 9.730
SA - Sud America 1.074
Continente sconosciuto - Info sul continente non disponibili 456
AF - Africa 251
OC - Oceania 136
Totale 34.939
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.118
RU - Federazione Russa 3.200
IT - Italia 3.178
CN - Cina 3.132
SG - Singapore 2.871
HK - Hong Kong 1.192
KR - Corea 897
BR - Brasile 831
VN - Vietnam 732
IE - Irlanda 582
BD - Bangladesh 536
FI - Finlandia 449
PL - Polonia 449
FR - Francia 356
IN - India 340
DE - Germania 323
CA - Canada 322
SE - Svezia 291
GB - Regno Unito 218
JP - Giappone 199
ID - Indonesia 193
NL - Olanda 153
JO - Giordania 149
AU - Australia 134
AT - Austria 104
AR - Argentina 86
CH - Svizzera 86
ES - Italia 86
MX - Messico 79
TR - Turchia 63
UA - Ucraina 52
NG - Nigeria 45
IQ - Iraq 44
EC - Ecuador 43
ZA - Sudafrica 43
PK - Pakistan 42
TW - Taiwan 42
AE - Emirati Arabi Uniti 41
BE - Belgio 33
IL - Israele 33
MA - Marocco 31
CO - Colombia 29
MY - Malesia 25
BJ - Benin 24
CI - Costa d'Avorio 24
DK - Danimarca 24
CL - Cile 22
HU - Ungheria 22
VE - Venezuela 21
SA - Arabia Saudita 20
UZ - Uzbekistan 20
CZ - Repubblica Ceca 19
EG - Egitto 18
PH - Filippine 17
GR - Grecia 16
JM - Giamaica 16
LU - Lussemburgo 16
KE - Kenya 15
IR - Iran 14
DZ - Algeria 13
PE - Perù 13
PY - Paraguay 13
CR - Costa Rica 12
HN - Honduras 12
TH - Thailandia 12
TT - Trinidad e Tobago 12
UY - Uruguay 12
LT - Lituania 11
TN - Tunisia 11
NP - Nepal 9
PT - Portogallo 9
GT - Guatemala 8
PR - Porto Rico 8
AL - Albania 7
BB - Barbados 7
PA - Panama 7
BW - Botswana 6
DO - Repubblica Dominicana 6
LV - Lettonia 6
NO - Norvegia 6
AZ - Azerbaigian 5
BH - Bahrain 5
HR - Croazia 5
OM - Oman 5
RO - Romania 5
SN - Senegal 5
BY - Bielorussia 4
KW - Kuwait 4
KZ - Kazakistan 4
BG - Bulgaria 3
BO - Bolivia 3
BS - Bahamas 3
EE - Estonia 3
ET - Etiopia 3
GA - Gabon 3
GP - Guadalupe 3
KG - Kirghizistan 3
KH - Cambogia 3
LK - Sri Lanka 3
MD - Moldavia 3
Totale 34.435
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.035
Singapore 2.202
Ashburn 2.013
Hefei 1.087
Hong Kong 1.028
Seoul 876
San Jose 746
Dublin 575
Milan 545
Warsaw 434
Council Bluffs 396
Los Angeles 331
Florence 330
Helsinki 305
Beijing 294
Rome 283
Fairfield 280
Chandler 270
New York 222
Ho Chi Minh City 218
Buffalo 216
The Dalles 191
Moscow 181
Hanoi 180
Lauterbourg 176
Seattle 161
Jakarta 157
Dallas 152
Tokyo 143
Boardman 139
Kent 132
Munich 131
Melbourne 123
Shanghai 116
Woodbridge 112
Houston 110
Wilmington 109
Cambridge 104
Lawrence 101
Mumbai 95
São Paulo 95
Toronto 94
Paris 93
Vienna 93
Altamura 92
Boston 92
Chicago 82
Bengaluru 77
Naples 77
Lappeenranta 74
London 67
Turin 67
Princeton 61
Bern 59
Ann Arbor 58
Turku 58
Bologna 53
Pune 50
Brescia 49
West Jordan 48
Guangzhou 47
Abuja 44
Figino 44
Frankfurt am Main 43
Orem 40
Bari 39
Shenzhen 37
Bar Harbor 36
Madrid 35
San Diego 35
Genoa 32
Da Nang 31
Montreal 31
Haiphong 30
San Francisco 30
Atlanta 28
Chennai 28
Amsterdam 27
Brooklyn 27
Palermo 27
Vancouver 27
Miano 26
Taipei 25
Tianjin 25
Yubileyny 25
Cotonou 24
Johannesburg 24
Venice 24
Abidjan 23
Charlotte 22
Philadelphia 22
Redondo Beach 22
Verona 22
Brussels 21
Catania 21
Jacksonville 21
Phoenix 21
Baghdad 20
Groningen 20
Mexico City 20
Totale 20.884
Salva come PNG Salva come JPEG
Nome #
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer 1.089
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer 447
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy 341
Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC 294
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification 281
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 275
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 258
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients 258
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 252
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 251
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 248
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 247
Identification of predictive biomarkers of clinical benefits to immunotherapy in pre-treated advanced non-small cell lung cancer: a retrospective observational study 245
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 242
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 232
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 231
SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY PERCUTANEOUS ETHANOL INJECTION: A 10-YEAR EXPERIENCE. 225
Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature 224
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles 221
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 220
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy 218
Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification 216
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation 214
Single-stage operation using hypothermic circulatory arrest to remove uterine intravenous leiomyomatosis extended to the vena cava and right atrium 211
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 208
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 207
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 205
Current status and future perspectives in HER2 positive advanced gastric cancer 203
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report 203
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 203
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study 199
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 197
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma 196
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study 193
Circulating tumour cells in colorectal cancer 193
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 190
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 190
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 189
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 188
Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients 187
Somatostatin analogs in pregnant patients with neuroendocrine tumor 187
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population 187
Real-world study of everolimus in advanced progressive neuroendocrine tumors 187
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 187
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 186
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 186
Analysis and optimization of clinical pathway of a cancer patient in a University Hospital 185
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors 185
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis 184
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 184
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" 183
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes 183
Results of the observational prospective RealFLOT study 183
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 183
Delineation of gastrointestinal tumors biopsies using a fluorescence lifetime imaging optical fiber probe 183
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 183
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression 182
Growth arrest-specific 5 lncRNA as a valuable biomarker of chemoresistance in osteosarcoma 181
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 180
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 180
Analysis of molecular and clinical markers of resistance to bacillus of Calmette-Guérin immunotherapy in patients with urothelial non-muscle invasive bladder cancer 179
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs 179
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 179
Occurrence of Dysgeusia in Patients Being Treated for Cancer 179
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival 178
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 178
Soft tissue sarcoma: An insight on biomarkers at molecular, metabolic and cellular level 178
Systemic Sclerosis Association with Malignancy 177
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study 177
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment 176
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 176
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program 175
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 175
ROS1 rearrangements are uncommon in biliary tract cancers 173
Robotic approach with neoadjuvant chemotherapy in adult Wilms' tumor: A feasibility study report and a systematic review of the literature 173
Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma 173
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib 173
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 173
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? 172
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25) 171
Time-resolved autofluorescence imaging of freshly excised liver biopsies using an optical fiber probe 169
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation 169
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 168
KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients 168
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors 167
Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature 166
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 165
Successful Use of Cemiplimab in a Very Elderly Patient With Cutaneous Squamous Cell Carcinoma 165
Induction chemotherapy followed by pleurectomy decortication and hyperthermic intraoperative chemotherapy (Hithoc) for early-stage epitheliod malignant pleural mesothelioma—a prospective report 165
Liquid biopsy in colorectal cancer: No longer young, but not yet old 162
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors 161
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 161
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 161
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 160
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 157
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) 157
Everolimus in pancreatic neuroendocrine carcinomas G3 157
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 156
Deciphering the Renal tumOr microenvironment to PersonaLize immunE-targeted Treatment (DROPLET): transcriptomic profiling of primary and secondary lesions identified a potential crosstalk between MARCO+ macrophages and deregulated cancer-cell proliferation in mediating progression and therapy response of advanced renal cell carcinoта. 156
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy 156
Totale 20.530
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.184
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.184
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022452 0 33 45 13 18 12 13 65 34 22 69 128
2022/20232.132 103 285 67 153 109 413 301 272 237 31 78 83
2023/20241.905 39 98 168 129 117 270 113 393 68 197 155 158
2024/202510.821 311 913 580 1.591 2.563 1.508 381 613 610 383 568 800
2025/202616.846 1.626 2.006 2.018 1.400 1.548 547 1.710 917 1.148 1.150 963 1.813
2026/20271.389 979 410 0 0 0 0 0 0 0 0 0 0
Totale 34.939